KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Non-cash Items (2020 - 2023)

Ginkgo Bioworks Holdings posted quarterly Non-cash Items of $14.6 million for Q2 2023, down 21.13% year-on-year from $18.5 million in Q2 2022, and up 32.89% on a QoQ basis from $11.0 million in Q1 2023.

Ginkgo Bioworks Holdings (DNA) has 4 years of Non-cash Items data on file, last reported at $14.6 million in Q2 2023.

  • For the quarter ending Q2 2023, Non-cash Items fell 21.13% year-over-year to $14.6 million; the trailing twelve-month figure through Jun 2023 stood at $14.6 million (down 21.13% YoY), and the FY2022 full-year result was $9.5 million, down 94.86% from the prior year.
  • Non-cash Items for Q2 2023 stood at $14.6 million, up from $11.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $386.0 million in Q4 2020 and bottomed at $9.5 million in Q4 2022.
  • The 4-year median for Non-cash Items is $50.9 million (2022), against an average of $120.9 million.
  • The widest annual swing landed in 2022, when Non-cash Items slumped 94.86%; it then retreated 21.13% in 2023.
  • A 4-year view of Non-cash Items shows it stood at $386.0 million in 2020, then tumbled by 51.91% to $185.6 million in 2021, then plunged by 94.86% to $9.5 million in 2022, then soared by 53.12% to $14.6 million in 2023.
  • The last three Non-cash Items figures came in at $14.6 million (Q2 2023), $11.0 million (Q1 2023), and $9.5 million (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Ginkgo Bioworks Holdings 542.03 Mn 542.03 Mn 16.38 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 14.61 Mn
Jun 30, 2023 14.61 Mn
Mar 31, 2023 11.00 Mn
Mar 31, 2023 11.00 Mn
Dec 31, 2022 9.54 Mn
Dec 31, 2022 9.54 Mn
Sep 30, 2022 50.89 Mn
Sep 30, 2022 50.89 Mn
Jun 30, 2022 18.53 Mn
Jun 30, 2022 18.53 Mn
Mar 31, 2022 74.48 Mn
Mar 31, 2022 74.48 Mn
Dec 31, 2021 185.62 Mn
Dec 31, 2021 185.62 Mn
Sep 30, 2021 337.10 Mn
Sep 30, 2021 337.10 Mn
Dec 31, 2020 386.02 Mn
Dec 31, 2020 386.02 Mn